Edas-117 Larinol drops 25 ml

Questions, answers, reviews on the drug Larinol Edas-117

You can look at questions about the drug, as well as ask your question to a specialist, using a free consultation with a pharmacist or pharmacist.
The information provided is intended for medical and pharmaceutical professionals. The most accurate information about the drug is contained in the instructions supplied with the packaging by the manufacturer. No information posted on this or any other page of our website can serve as a substitute for personal contact with a specialist.

Edas-117 Larinol drops 25 ml

—>

Mode of application

Take orally outside meals, 5 drops on a piece of sugar or in a teaspoon of water 3 times a day. For children, on the recommendation of a doctor: up to 2 years – 1 drop, from 2 to 5 years – 2 drops, from 5 to 10 years – 3 drops, over 10 years – 4 drops 3 times a day.

Description

Complex (multicomponent) drug LARINOL EDAS-117.

The components included in the drug, complementary, affect the central and autonomic nervous, lymphatic, immune systems, and mucous membranes.

For possible choice, taking into account concomitant diseases, and ease of use, LARINOL EDAS-917 granules of identical composition are produced.

Characteristic symptoms associated with the use of individual components:

— Kalium bichromicum (Kalium bichromicum) — Catarrhal inflammation of the mucous membranes of the upper respiratory tract, paranasal sinuses. Pain and ulceration of the mucous membranes of the nose and pharynx. Impaired nasal breathing and sense of smell. Dry nasopharynx. Sore throat. Dry cough. Headache.

- Hepar sulphuris (Hepar sulfur) - Inflammation of the mucous membranes of the paranasal sinuses and nose, pharynx. Especially chronic sluggish purulent processes. Promotes faster removal of purulent discharge and recovery. It is used as a “drainage” agent for allergic and inflammatory swelling of the mucous membranes. Increased sensitivity to cold and drafts.

- Atropa bella-donna (Belladonna) - Swelling and pain in the throat and nasopharynx. Nosebleeds. Dryness and soreness in the throat and nasopharynx, larynx, trachea. Hoarseness and loss of voice. Attacks of dry, spasmodic cough. General and local inflammatory processes in the hyperemia phase.

— Echinacea purpurea (Echinacea) — Inflammation of the mucous membrane of the nasopharynx, paranasal sinuses, accompanied by pain and ulceration. Swelling of the mucous membrane. Nasal congestion. Impaired immune processes.

- Thuja occidentalis (Thuja) - Prolonged runny nose with mucous or thick greenish discharge, hypertrophy of the nasal mucosa. Atrophy of the mucous membrane and dryness in the nose. Adenoid vegetations. Nasal polyps. Chronic, sluggish inflammatory process of the ear with serous or purulent discharge.

These symptoms are characteristic of rhinitis with mucous or purulent discharge, acute and chronic inflammatory diseases of the paranasal cavities, adenoids and nasal polyps, laryngitis, pharyngitis.

When treating acute rhinitis, it is advisable to additionally instill drops of RINITOL EDAS-131 into the nose, and in the case of chronic rhinitis, adenoids and nasal polyps - Thuya EDAS-801 oil.

For otitis, a gauze turunda with TUYA EDAS-801 oil is inserted into the external auditory canal.

To prevent these diseases, we recommend BIOENERGOTONIC EDAS 03-01, which contains trace elements: zinc, manganese, selenium, vitamin C and the biologically active components of echinacea and bee bread. LARINOL EDAS-117 is used to treat adults and children. Compatible with other pharmaceuticals. Dispensed without a doctor's prescription.

TREATMENT SCHEME:

— SINUSITIS — inflammation of the maxillary (maxillary) paranasal sinus. Which is accompanied by increasing discomfort in the nose, headache, yellow-green nasal discharge and fever.

Before starting treatment of chronic diseases and to increase the effectiveness of homeopathic remedies, it is recommended to cleanse the body with Karsat “EDAS-136” (drops) or Karsat “EDAS-936” (granules). Which activates the excretory functions of the body, thereby cleansing the body of toxins, radionuclides, and chemicals.

Larinol "EDAS-117" (drops) or Larinol "EDAS-917" (granules) 5 drops/granules 3 times a day for 3 weeks.

If the disease is accompanied by rhinitis (runny nose), then additionally take nasal drops Rinitol “EDAS-131” (nasal drops) 5 drops in each nasal passage.

To consolidate the result and increase immunity, it is also recommended that Propolan “EDAS – 150” (drops) 5 drops 2-3 times a day for 4 weeks, if you are allergic to bee products, then replace it with 1 tablet of ECHINACEA. 3 times a day after meals.

The course of treatment can be repeated after 1 week. We recommend that after completing the course of treatment, especially with pharmaceuticals, you cleanse the liver with the drug Hepa “EDAS – 953”, for 2 weeks, 5 granules 3 times a day.

Note: all drugs (both drops and granules) are applied within 20-30 minutes. before meals or 1 hour after, consistently every 5-7 minutes. one after another.

The dosage is based on an adult; children by age:

up to 2 years - 1-2 granules, from 2 to 5 years - 2-3 granules, from 5 to 10 years - 3-4 granules, over 10 years - 4-5 granules, three times a day .

Side effects

Doesn't have it.

Larinol EDAS-117 (917)

According to the Clinical Study Protocol, approved by the specialized commission of IDKELS, a clinical study was conducted, the purpose of which was to study the effectiveness, tolerability, safety, as well as unwanted and side effects of the complex homeopathic drug Larinol EDAS-117 (drops) in the treatment of patients with acute and chronic sinusitis in exacerbation phase (hereinafter referred to as acute sinusitis).

Patients were selected according to inclusion criteria in accordance patient age over 18 years; body temperature no more than 37.5°C; availability of informed consent of patients to participate in a clinical trial.

The criteria for excluding patients body temperature above +37.5 C; patients using medications that may affect study results; severe concomitant diseases requiring systemic therapy; individual intolerance to the drug; pregnancy and breastfeeding.

In total, we observed 60 patients of both sexes with acute sinusitis aged from 18 to 60 years (average age 39.7 +1.6 years). Of these, 45% were male patients and 55% were female patients. The patients comprised 2 comparable groups – the main and control groups, 30 patients in each (Table 1). There were no significant differences in age and gender between the groups.

Pain syndrome (headache, pain in the affected sinus, pain on palpation of the facial wall of the maxillary sinus) and symptoms of nasal congestion, nasal discharge, impaired nasal breathing, disturbance of smell on the affected side, lacrimation, chills, rhinoscopy picture, radiographic picture of the sinus were assessed by verified 3 and 5 point scale.

• Headache: 0 points – no symptom; 1 point – pain is rare and short-term, quickly goes away on its own; 2 points – often bothers you, but goes away easily with adequate pharmacotherapy; 3 points – the pain is severe, prolonged, and difficult to respond to pharmacotherapy.
• Pain in the affected sinus: 0 points – no symptom; 1 point – moderately severe periodic pain; 2 points – moderately severe constant pain; 3 points – severe pain, patients are forced to constantly take analgesics, work ability is preserved; 4 points – severe pain that interferes with physical and mental work. Analgesics provide temporary relief; 5 points – severe excruciating pain, preventing sleep at night, not relieved by analgesics, interfering with physical work.
• Pain on palpation of the facial wall of the maxillary sinus: 0 points – no symptom; 1 point – very mild pain; 2 points – mild pain; 3 points – moderate pain; 4 points – severe pain; 5 points – very severe pain.
• Nasal congestion: 0 points – no symptom; 1 point – episodic nasal congestion, goes away on its own; 2 points – constant nasal congestion, corrected by pharmacotherapy; 3 points – constant nasal congestion, difficult to correct with pharmacotherapy.
• Nasal discharge: 0 points – no symptom; 1 point – not abundant (but more than usual), thin, light-colored discharge; 2 points – constant, abundant, liquid, light, odorless discharge; 3 points – copious, thick discharge with a greenish tint and a putrid odor.
• Nasal breathing disturbance: 0 points – no symptom; 1 point – episodic difficulties in nasal breathing, go away on their own; 2 points – the presence of significant and prolonged difficulties in nasal breathing, which are easily relieved by pharmaceutical therapy; 3 points – complete blockade of nasal breathing (open mouth breathing), which is difficult to respond to pharmacotherapy.
• Smell disorder on the affected side 0 points 1 point – slight decrease in sense of smell (up to 25% of normal); 2 points – significant decrease in sense of smell (up to 50% of normal); 3 points – complete absence of sense of smell.
• Lacrimation: 0 points – no symptom; 1 point – episodic lacrimation; 2 points – constant lacrimation, easily relieved by pharmacotherapy; 3 points – constant lacrimation, difficult to correct with pharmacotherapy.
• Chills: 0 points – no symptom; 1 point – slight trembling and twitching of the facial muscles and fingers (chilling), goes away on its own; 2 points – coldness and trembling of the whole body, emanating from the inside, is relatively easily controlled by adequate pharmaceutical therapy; 3 points – tremendous chills with profuse sweat, difficult to control with the help of hormones (prednisolone) and drugs (promedol, omnopon).
• Rhinoscopy picture: 0 points – no deviations from the norm; 1 point – slight hyperemia and swelling of the nasal mucosa; 2 points – severe hyperemia and swelling of the nasal mucosa, proliferation of connective tissue is noted, and the presence of discharge in the middle nasal meatus is noted; 3 points - the entire nasal mucosa is significantly hyperemic and edematous, significant growths of connective tissue are noted, the presence of discharge in the middle nasal passage, purulent discharge is found on the back wall of the pharynx.
• X-ray picture of the sinus: 0 points – no deviations from the norm; 1 point – darkening is detected in a limited area of ​​the maxillary sinus; 2 points – there is diffuse darkening of the sinus and moderate local pain; 3 points – there is a total darkening of the maxillary sinus, swelling of the cheek, severe local pain, accompanied by chills.

During the initial examination, we collected general data, complaints and medical history of the patient, assessed the clinical manifestations of acute sinusitis taking into account the criteria for inclusion in and exclusion from groups, a general blood and urine test, thermometry, rhinoscopy, and radiography of the maxillary sinus. Pathology concomitant with the underlying disease was identified to prescribe, if necessary, additional drug therapy. Test puncture of the maxillary sinus according to indications.

After 7 days - assessment of the symptoms of the disease, blood test for leukocytosis and ESR, thermometry, rhinoscopy, assessment of tolerability and effectiveness of the drug.

After 15 days - assessment of the symptoms of the disease, general blood and urine analysis, thermometry, rhinoscopy, x-ray of the maxillary sinus, assessment of tolerability and effectiveness of the drug.

A post-registration randomized open clinical trial was devoted to studying the effectiveness of homeopathic drops Larinol EDAS-117 in comparison with the basic drug acetylsalicylic acid in the treatment of patients with acute sinusitis.

Treatment regimen in the control group:

• 1. Ensuring a good outflow of contents from the sinus by instilling a 0.1% naphthyzine solution or a 0.2% galazolin solution into the nose.
• 2. Acetylsalicylic acid 0.5 g 3 times a day until acute effects stop (5-7 days), then maintenance doses (0.25 g 2 times a day).
• 3. Vitrum 1 tablet 1 time per day. 4. UHF – therapy No. 6-10. 5. The course of treatment is 15 days.

Treatment regimen in the main group: instead of acetylsalicylic acid, patients received GoLS Larinol EDAS-117, 5 drops on a piece of sugar or in a teaspoon of water 3 times a day without meals for 15 days.

The effectiveness of treatment of patients was assessed by the degree of reduction of pain and symptoms of nasal congestion, nasal discharge, impaired nasal breathing, disturbance of smell on the affected side, lacrimation, chills, low-grade fever, leukocytosis, accelerated ESR, rhinoscopy picture, radiographic picture of the sinus. We found pathology associated with the underlying disease without exacerbation; it did not require additional drug correction and could not affect the results of the ongoing clinical trial. There were no significant changes in clinical blood tests (except for leukocytosis and accelerated ESR) and urine. Due to the progressive course of the disease, 3 patients (2 from the main and 1 from the control group) underwent puncture of the maxillary sinus on the 6-7th day of treatment, as a result of which the diagnosis of acute purulent sinusitis was confirmed. Patients were excluded from the study to continue treatment in a specialized department. Statistical processing of the study results was carried out using Student's t-test.

As shown in Table 2, before treatment, the symptoms of acute sinusitis, lacrimation and chills in patients of both groups were characterized by a moderate degree of severity and ranged from 1.6+0.18 -1.7+0.19 points in the main group and 1.6+ 0.17-1.7+0.19 points in the control group on a 3-point rating scale. Body temperature was subfebrile and amounted to 37.4+0.08°C in the main group and 37.3+0.09°C in the control group. Dynamic observation of patients showed a complete reduction of these symptoms after 7 days of treatment, both in the main and control groups (p

After 7 days of treatment, a significant decrease in the severity of these symptoms was noted, as in the main group of patients receiving homeopathic drops Larinol EDAS-117 (1.3±0.17 - 1.6±0.18 points; p

At the end of treatment, symptoms of nasal congestion and discharge, and impaired nasal breathing were completely reduced in both the main and control groups (p

Before treatment, patients in both groups had moderate leukocytosis and a moderate increase in ESR, amounting to 12.2±0.8 thousand in 1 μl, respectively, and 22.1±1.8 mm/h in the main group and 11.9±0.7 thousand in 1 µl and 21.9±2.0 mm/h in the control group. At the end of treatment, the number of leukocytes in the blood and ESR in patients of both groups reached normal values, amounting to 8.0 ± 0.4 thousand in 1 μl and 8.9 ± 0.7 mm/h in the main group and 7.8 ± 0. 3 thousand in 1 µl and 9.1±0.8 mm/h in the control group (p

After 7 days of treatment, patients in both groups showed a significant decrease in the severity of the rhinoscopic picture (p

Before treatment, the x-ray of the maxillary sinus of patients in both groups showed diffuse and, in some patients, total darkening, which was estimated at 2.5 ± 0.27 points in the main group and 2.4 ± 0.25 points in the control group (Table 2). At the end of treatment, the severity of the x-ray picture of the maxillary sinus was reduced by 88.0% and amounted to 0.3±0.08 points from the outcome in the main group and by 91.7% (0.2±0.05 points) in the control group and was characterized by residual darkening of the maxillary sinus in a small, limited area (p

At the end of treatment, the average total (? M) reduction in symptoms of acute sinusitis was 96.7% in the main group of patients receiving Larinol EDAS-117, and 97.7% in the control group, where patients received the basic drug acetylsalicylic acid (Table 3 ). There were no significant differences between the severity of symptoms of acute sinusitis in patients of the main and control groups throughout the treatment (Table 2).

In the main group of patients receiving homeopathic drops Larinol EDAS-117, good results were obtained in 24 patients (80.0%), satisfactory - in 4 (13.3%) and unsatisfactory - in 2 (6.7%), in which showed a progressive course of the disease with an increase in symptoms and a deterioration in general condition on the 6-7th day of treatment. They underwent a puncture of the maxillary sinus, as a result of which the diagnosis of acute purulent sinusitis was confirmed. Patients were excluded from the study to continue treatment in a specialized department (Table 5).

In the control group, where patients received the basic drug acetylsalicylic acid, good results were recorded in 26 patients (86.7%), satisfactory - in 3 patients (10.0%) and unsatisfactory (the reason is the same as in the main group) - in 1 patient (3.3%). The complex homeopathic drug Larinol EDAS-117 is safe to use, it is well tolerated by patients, and in no case were there any side effects or undesirable effects (Table 4).

A clinical study has shown a fairly high effectiveness of homeopathic drops Larinol EDAS-117 in complex therapy of patients with acute sinusitis in comparison with the basic drug acetylsalicylic acid. Please note the following:

• symptoms of acute sinusitis: lacrimation, chills and elevated body temperature are equally well reduced by both homeopathic drops Larinol EDAS-117 and the basic drug acetylsalicylic acid after 7 days of treatment;
• at the end of treatment, the average total (? M) reduction in symptoms of acute sinusitis was 96.7% in the main group of patients receiving Larinol EDAS-117, and 97.7% in the control group, where patients received the basic drug acetylsalicylic acid;
• in the main group of patients who received homeopathic drops Larinol EDAS-117, good results were obtained by 6.7% less, and unsatisfactory results by 3.4% more than in the control group, where patients received the basic drug acetylsalicylic acid;
• There were no significant differences between the severity of symptoms of acute sinusitis in patients of the main and control groups throughout the treatment;
• Larinol EDAS-117 is safe to use and is well tolerated by patients. In no case were there any side and/or undesirable effects;
• The treatment regimen for patients with acute sinusitis with the homeopathic drug Larinol EDAS-117 proposed by the developers is the most optimal and convenient for use.

Thus, the homeopathic medicine Larinol EDAS-117 in its effectiveness in the complex therapy of patients with acute and chronic sinusitis in the acute phase is practically not inferior (or inferior only slightly: 3.4% more unsatisfactory results) to the recognized standard basic drug acetylsalicylic acid, which is definitely a great success. Larinol EDAS-117 is safe to use, well tolerated by patients, does not cause side and/or undesirable effects, which allows us to recommend it for widespread introduction into medical practice as a drug of choice in the treatment of patients with acute and chronic sinusitis in the acute phase.